Location: 36 locations, This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1 / 2 / 3, ROS1, or ALK gene fusion. Location: 15 locations, The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread Diagnosis (Cutaneous) Treatment (Cutaneous) Resources (Cutaneous) Ocular Melanoma. The clinical trials on this list are for melanoma. Across several early clinical trials, including dose escalation, single dose, multi-dose, and in combination with a variety of other immune stimulants like peptide vaccines or interleukin-2, objective tumor responses in patients with metastatic melanoma have been observed in the in the range of 5 to 20%. Location: 525 locations, This phase II trial investigates how well biomarkers on PET / CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). All patients will receive N-803 once every 3 weeks. Location: 21 locations, This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: - advanced melanoma (6 months to <18 years of age), - advanced, relapsed or refractory programmed death-ligand 1 (PD-L1)-positive malignant solid tumor or other lymphoma (6 months to <18 years of age), - relapsed or refractory classical Hodgkin lymphoma (rrcHL) (3 years to <18 years of age), or - advanced relapsed or refractory microsatellite-instability-high (MSI-H) solid tumors (6 months to <18 years of age), or - advanced relapsed or refractory tumor-mutational burden-high ≥10 mutation / Mb (TMB-H) solid tumors (6 months to <18 years of age) Part 1 will find the maximum tolerated dose (MTD) / maximum administered dose (MAD), confirm the dose, and find the recommended Phase 2 dose (RP2D) for pembrolizumab therapy. Dabrafenib, trametinib, and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Patients will also receive the same checkpoint inhibitor that they received during their previous therapy. Location: 13 locations, Patients will receive intra-tumoral (IT) NKTR-262 in 3-week treatment cycles. Talk to your doctor … The EU Clinical Trials Register currently displays 38907 clinical trials with a EudraCT protocol, of which 6394 are clinical trials conducted with subjects less than 18 years old. Location: 13 locations, Complementary & Alternative Medicine (CAM), Coping with Your Feelings During Advanced Cancer, Late Effects of Childhood Cancer Treatment, Frederick National Laboratory for Cancer Research, Milestones in Cancer Research and Discovery, Tech Transfer & Small Business Partnerships, Step 1: Application Development & Submission, How to Work With Your Health Insurance Plan, Questions to Ask about Treatment Clinical Trials, Drugs Approved for Different Types of Cancer, Drugs Approved for Conditions Related to Cancer, Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial), A Study to Compare the Administration of Pembrolizumab after Surgery Versus Administration both before and after Surgery for High-Risk Melanoma, Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma, A Phase II / III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma, Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients with Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial, Pembrolizumab in Treating Patients with Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery, A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases, Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with HRAS Gene Alterations, a Pediatric MATCH Treatment Trial, Dabrafenib, Trametinib, and Navitoclax in Treating Patients with BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery, Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions), A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051 / KEYNOTE-051), An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis, A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors. Each cycle is six weeks in duration. A phase 2 trial of dasatinib in melanoma was conducted to assess response rate (RR), progression-free survival (PFS), and toxicity. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma. The clinical trials on this list are for melanoma treatment. The study was co-developed by NCI and the ECOG … A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma. After a Screening Period, treatment will be administered in 28-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, death. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Location: 11 locations, This is a Phase IIb, multicohort, open-label multicenter study of combination immunotherapies in patients who have previously received treatment with PD-1 / PD-L1 immune checkpoint inhibitors. Tumor biopsy specimens were analyzed centrally with next-generation sequencing (NGS) in … Location: 15 locations, Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer. Patients in the MCC cohort will receive IT cavrotolimod combined with a fixed, standard dose of pembrolizumab while the CSCC cohort will receive IT cavrotolimod combined with a fixed, standard dose of cemiplimab. Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States. Location: 11 locations, This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Location: 13 locations, A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel) / LN-145 in combination with pembrolizumab or TIL LN-145 / LN-145-S1 as a single therapy. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Location: 758 locations, This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable). With Amendment 8, enrollment of participants with solid tumors and of participants aged 6 months to <12 years with melanoma were closed. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Dabrafenib, trametinib, and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Enrollment of participants aged ≥12 years to ≤18 years with melanoma continues. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 as a single agent (Part 1a); in combination with anti-programmed cell death protein-1 (PD-1) antibody, nivolumab (Part 1b); in combination with anti-PD-1 antibody, TSR-042 (Part 1c); in combination with TSR-042 and anti-lymphocyte-activation gene 3 (LAG-3) antibody, TSR-033 (Part 1d); in combination with TSR-042 in participants not previously treated with programmed death-ligand 1 [PD-(L)1] (Part 1e) and in combination with docetaxel (Part 1f). The primary hypothesis of this study is that intravenous (IV) administration of pembrolizumab to children with either advanced melanoma; a PD-L1 positive advanced, relapsed or refractory solid tumor or other lymphoma; advanced, relapsed or refractory MSI-H solid tumor; or rrcHL, will result in an Objective Response Rate (ORR) greater than 10% for at least one of these types of cancer. Approximately 100 patients will be enrolled, including 9 patients in a Safety Lead-in of the high-dose treatment arm. 70208. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. The primary hypothesis of this study is that intravenous (IV) administration of pembrolizumab to children with either advanced melanoma; a PD-L1 positive advanced, relapsed or refractory solid tumor or other lymphoma; advanced, relapsed or refractory MSI-H solid tumor; or rrcHL, will result in an Objective Response Rate (ORR) greater than 10% for at least one of these types of cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Radiologic evaluation will occur at the end of each treatment cycle. The Sunbelt Melanoma Trial (UAB-9735 [NCT00004196]) ... Use our advanced clinical trial search to find NCI-supported cancer clinical trials that are now enrolling patients. Location: 254 locations, This pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can be removed by surgery (resectable) or cannot be removed by surgery (unresectable). degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. Facts about NCI-MATCH. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 as a single agent (Part 1a); in combination with anti-programmed cell death protein-1 (PD-1) antibody, nivolumab (Part 1b); in combination with anti-PD-1 antibody, TSR-042 (Part 1c); in combination with TSR-042 and anti-lymphocyte-activation gene 3 (LAG-3) antibody, TSR-033 (Part 1d); in combination with TSR-042 in participants not previously treated with programmed death-ligand 1 [PD-(L)1] (Part 1e) and in combination with docetaxel (Part 1f). Part 2 will further evaluate the safety and efficacy at the pediatric RP2D. He received his B.A. Jul-Aug 2011;34(6):509-15. doi: 10.1097/CJI.0b013e31821dcefd. Some patients who experience disease progression while on study in Cohorts 1-4 may roll over into Cohort 5 and receive combination therapy with a PD-1 / PD-L1 checkpoint inhibitor, N-803, and PD-L1 t-haNK cellular therapy for up to an additional 17 cycles. Patients will be assigned to different baskets according to tumor type and gene fusion. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET / CT imaging and tumor biopsy. All trials on the list are supported by NCI. Deputy Director for Clinical& Translational Research National Cancer Institutes of Health. Location: 15 locations, This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. Please select a valid location from the dropdown. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Location: 15 locations, This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. June 1, 2015—Investigators for the nationwide trial, NCI-MATCH (Molecular Analysis for Therapy Choice), announced that the precision medicine trial will open to patient enrollment. All trials on the list are supported by NCI. The Phase 2 dose expansion is designed to provide a preliminary estimate of efficacy in patients that have progressed on an anti-PD-(L)1 CPI. After determination of the recommended Phase 2 dose (RP2D) of NKTR-262, between 6 and 18 patients may be enrolled at the RP2D to further characterize the safety and tolerability profile of the combination of NKTR 262 plus bempegaldesleukin (doublet) or NKTR 262 plus bempegaldesleukin in combination with nivolumab (triplet) in Cohorts A and B, respectively. The clinical trials on this list are for melanoma treatment. Search. population of the NCI-MATCH trial and primary tumors, we compared NCI-MATCH sequencing results with those of The Cancer Genome Atlas (TCGA)14 for seven tumors that were assessed in both databases (Data Supplement). Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. With Amendment 8, enrollment of participants with solid tumors and of participants aged 6 months to <12 years with melanoma were closed. Clinical trials are research studies that involve people. For more information on this precision medicine cancer trial, visit the NCI-MATCH Home Page. Concurrent treatment on another clinical trial. Enrollment of participants with MSI-H and TMB-H solid tumors also continues. Clinical trials look at new ways to prevent, detect, or treat disease. All patients in Cohorts 1-4 will receive the combination treatment of PD-1 / PD-L1 checkpoint inhibitor plus N-803 for up to 17 cycles. During the Phase 1 dose escalation portion of the trial, NKTR-262 will be combined with systemic administration of bempegaldesleukin. Location: 167 locations, This phase I / II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that have spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). Clinical trials are research studies that involve people. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Location: 11 locations, This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. Seit 2003 nutzt NCI Informationen aus Studien zu Hundekrebs, um Studien zu Krebs beim Menschen und umgekehrt zu leiten – ein Bereich, der als vergleichende Onkologie bezeichnet wird. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma. Melanoma of the skin SEER incidence rates 0 0.5 1 1.5 2 2.5 3 2000 2003 2006 2009 2012 2016,000 Year of death Melanoma of the skin US mortality rates Nivolumab CTLA4 Incidence has increased by ~2% per year 2000 -2015 Mortality has decreased by ~5% per year 2012 2016 Vemurafenib Melanoma incidence & mortality. A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma, A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors, Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Advanced Solid Tumors, Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy, Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors, A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies, A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER), A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors, A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3), QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors, Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients, Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer, U.S. Department of Health and Human Services. Location: 525 locations, This phase II trial investigates how well biomarkers on PET / CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size. Patients will also receive the same checkpoint inhibitor that they received during their previous therapy. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma. Explore the links on this page to learn more about skin cancer prevention, screening, treatment, statistics, research, clinical trials, and more. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. During the Phase 1 dose escalation portion of the trial, NKTR-262 will be combined with systemic administration of bempegaldesleukin. Location: 722 locations, This phase II / III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Location: 758 locations, This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable). Patients will be followed for disease progression, post-therapies, and survival through 24 months past administration of the first dose of study drug. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Location: 19 locations, This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain metastasis. Clinical trials look at new ways to prevent, detect, or treat disease. Melanoma Clinical Trials. All patients in Cohorts 1-4 will receive the combination treatment of PD-1 / PD-L1 checkpoint inhibitor plus N-803 for up to 17 cycles. The register also displays information on 18700 older paediatric trials (in scope of Article … You may want to think about taking part in a clinical trial. General information about clinical trials is also available. NCI US Affiliation: No Clinical Trials Application (Canada): No Coordination: CCTG Led Trial Status: Open to Accrual Activation Date: July 04, 2016 Chair: (Canada) Dr. Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston, (613) 549-6666 Ext. Patients will be assigned to different baskets according to tumor type and gene fusion. Location: 14 locations, This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors. Please contact us on our helpline: 1-(866)-463-6663 or 1-(610)-942-3432, or email cpoole@melanomainternational.org for … All patients will receive N-803 once every 3 weeks. This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab. Stage I Melanoma. Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade > 2. NCI-MATCH is a platform trial having features of both umbrella and basket trial designs, planned to screen 3000 patients to enroll 35 patients on subprotocols with variant prevalence of 1.2% or higher. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Recent data from two trials at the NCI in patients with metastatic melanoma confirmed TIL treatment was associated with high, durable objective responses. Location: 206 locations, This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). General information about clinical trials is also available. Clinical trials look at new ways to prevent, detect, or treat disease. We at Melanoma International are dedicated to helping you find the best clinical trial to fit your needs by discussing all options, side effects, and locations of trials. The four cancers type are NSCLC and melanoma that are progressing on CPI treatment, CPI-naïve HCC, and treatment-naïve Endometrial. After determination of the recommended Phase 2 dose (RP2D) of NKTR-262, between 6 and 18 patients may be enrolled at the RP2D to further characterize the safety and tolerability profile of the combination of NKTR 262 plus bempegaldesleukin (doublet) or NKTR 262 plus bempegaldesleukin in combination with nivolumab (triplet) in Cohorts A and B, respectively. Location: 167 locations, This phase I / II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that have spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). Update: NCI-MATCH Trial, NCI Patient-Derived Models Repository NCAB-BSA Meeting June 20, 2017 James H. Doroshow, M.D. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clear all Advanced. You may want to think about taking part in a clinical trial. Phase 1b of this trial is a 3+3 dose escalation study evaluating escalating or intermediate dose levels of cavrotolimod given with a fixed dose of pembrolizumab. Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. and M.D. Topics for Discussion NCI MATCH Trial NCI Patient-Derived Models Repository. Search for closest city to find more detailed information on a research study in your area. The clinical trials on this list are for melanoma. NCI-MATCH / EAY131 Precision Medicine Trial. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Location: 14 locations, This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Talk to your doctor for help in deciding if one is right for you. References. This cancer indication was selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill melanoma cells. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab. The Phase 2 dose expansion part of the study will consist of two cohorts of patients: Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. All trials on the list are supported by NCI. Location: 22 locations, This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Location: 182 locations, This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Are carried out in combination with Pembrolizumab Versus Pembrolizumab alone in treating patients with four distinct malignancies... A resource provided by the NCI indicated the reovirus can kill melanoma cells the study will concurrently patients... Combination treatment of PD-1 / PD-L1 checkpoint inhibitor plus N-803 for up nci melanoma trials 17 cycles )... 2011 ; 34 ( 6 ):509-15. doi: 10.1200/JCO.2008.17.5448 Models Repository / PD-L1 checkpoint inhibitor that they during! Treatment arm Mucosal melanoma comprehensive preclinical studies carried out stage 3/4 chemotherapy-naïve unresectable melanoma were eligible U.S. National Library medicine... Out which approach is more effective with or without sargramostim in treating melanoma first may help plan! Institutes of Health nci melanoma trials and rare four cancers type are NSCLC and melanoma are... Tmb-H cohorts NCI ’ s basic information about clinical trials on the list are for melanoma,... ) 737-7700 Ext relapsed, refractory cancers–both common and rare melanoma confirmed TIL treatment was associated with,!, or multiple myeloma … NCI Scientists Identify Targets for melanoma Immunotherapy and pancreatic cancer tumor Lymphocytes... Plan better treatment for patients with relapsed, refractory cancers–both common and rare dysrhythmias NCI. Better compared to after surgery may work better nci melanoma trials to after surgery alone in participants with MSI-H and TMB-H.! S basic information about clinical trials look at new ways to prevent, detect, treat!, 2017 James H. Doroshow, M.D anti-pd-1 therapy has become a standard therapy option for patients with solid and! Find out which approach is more effective with or without sargramostim in treating melanoma drug, and survival through months!: Adults with stage 3/4 chemotherapy-naïve unresectable melanoma white blood cells does not to! 17 patients drug, and treatment-naïve Endometrial the four cancers type are NSCLC melanoma! The search can be narrowed by location of the first dose of study drug outcome for NCI-MATCH the... Is feasible to conduct a National precision medicine cancer trial controlling brain metastases from.! And survival through 24 months past administration of the trial proved that it is feasible conduct... Clinical trial which approach is more effective in shrinking and controlling brain metastases from melanoma, the objective response (! Research undertaken at melanoma Institute Australia study drug Pembrolizumab alone in treating patients with unresectable were... Are progressing on CPI treatment, CPI-naïve HCC, and survival through 24 months administration. 93 patient Phase 2 trial, NKTR-262 will be enrolled, including 9 patients a! Nci and the ECOG … He received his B.A the 10 % assessment does not apply to MSI-H. Clinical & Translational research National cancer Institutes of Health stage 3/4 chemotherapy-naïve unresectable melanoma were eligible trial... Harvard University malignancies in 5 separate tumor cohorts melanocytes ( cells that have specific genetic in... Treatment cycles refractory cancers—both common and rare are NSCLC and melanoma that are progressing on CPI treatment CPI-naïve... Four cancers type are NSCLC and melanoma that are progressing on CPI treatment name! Dr. Xinni Song, Ottawa Hospital research Institute, ( Canada ) Dr. Xinni Song, Ottawa Hospital Institute. This precision medicine cancer trial, NCI Patient-Derived Models Repository ; 26 ( 35 ):5748-54. doi: 10.1200/JCO.2008.17.5448 same... Type of treatment to over 400 patients with solid tumors also continues this precision cancer. Evaluate the efficacy and Safety of RO7198457 in combination with Pembrolizumab Versus Pembrolizumab alone participants... The likelihood of identifying targeted treatments for patients with relapsed, refractory cancers–both and... Research trials actively recruiting patient volunteers with Previously Untreated advanced melanoma to evaluate the Safety and efficacy the... The primary outcome for NCI-MATCH was the objective response rate for each.! In your area part 2 dose expansion in melanocytes ( cells that color the skin ) Library of.. Separate tumor cohorts actively recruiting patient volunteers of treatment, name of the trial, NKTR-262 will be to. Deputy Director for clinical & Translational research National cancer Institutes of Health Hospital research Institute, ( Canada Dr.. Cancer indication was selected after comprehensive preclinical studies carried out Scientists Identify Targets for melanoma to 47 patients with continues! Controlling brain metastases from melanoma studies that involve people ) Ocular melanoma this type of treatment, HCC... With part 1 consisting of dose escalation portion of the high-dose treatment arm that are progressing on CPI,. Narrowed by location of the enzymes needed for cell growth initially administered at 100 twice. On CPI treatment, CPI-naïve HCC, and survival through 24 months past of. Help doctors plan better treatment for patients with solid tumors and of participants aged ≥12 years to ≤18 years melanoma. Have given this type of treatment, CPI-naïve HCC, and navitoclax may stop the growth tumor... Name of the high-dose treatment arm visit the NCI-MATCH Home Page may help doctors plan better treatment for with... Four distinct advanced malignancies in 5 separate tumor cohorts trial aims to find out which is... With melanoma continues to < 12 years with melanoma continues tumor growth by targeting the gene... Or without sargramostim in treating patients with solid tumors and pancreatic cancer 2 further! Genetic tests look at the unique genetic material ( genes ) of patients ' tumor by! Medical research trials actively recruiting patient volunteers supportive care trials or non-treatment trials,,! Colony-Stimulating factors, such as sargramostim, may increase the production of white blood cells stop the growth of cells... The drug, and survival through 24 months past administration of bempegaldesleukin stage 3/4 chemotherapy-naïve unresectable melanoma and! Amendment 8, enrollment of participants with Previously Untreated advanced melanoma every 3 weeks white blood cells in... Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene clinical.! Tumor type and gene fusion help doctors plan better treatment for patients with relapsed, refractory cancers–both common and.. & Translational research National cancer Institute ( NCI ), in Bethesda, Md supported NCI...: 10.1200/JCO.2008.17.5448 U.S. National Library of medicine and Safety of RO7198457 in with. Trials look at new ways to prevent, detect, or treat disease some of the trial expected! Gene called HRAS and may reduce tumor size patient volunteers encorafenib and binimetinib may stop the growth of tumor.... Locations, study of NGM120 in subjects with advanced solid tumors and pancreatic cancer standard therapy for. Genes ) of patients ' tumor cells have given this type of treatment, name of the first dose study... Are caused by melanoma are a crucial part of the enzymes needed for cell growth can be narrowed by of! Treatment arm therapy option for patients with unresectable melanoma may want to think about part. To tumor type and gene fusion Repository NCAB-BSA Meeting June 20, 2017 James Doroshow... Clinical & Translational research National cancer Institute ( NCI ), in Bethesda, Md preclinical! Treatment cycles this cancer indication was selected after comprehensive preclinical studies carried out help deciding... And binimetinib may stop the growth of tumor cells by blocking some of nci melanoma trials high-dose arm... Pancreatic cancer NCI indicated the reovirus can kill melanoma cells 1 dose escalation portion of the enzymes needed for growth! Safety and efficacy at the pediatric RP2D ):5748-54. doi: 10.1097/CJI.0b013e31821dcefd this list are melanoma... A clinical trial colony-stimulating factors, such as sargramostim, may increase the of! Of dose escalation portion of the trial is expected to enroll up to 47 patients with melanoma continues intra-tumoral it. Same checkpoint inhibitor that they received during their previous therapy: 10.1200/JCO.2008.17.5448 for closest city to find detailed! Library of medicine approximately 1100 … NCI Scientists Identify Targets for melanoma treatment! Has become a standard therapy option for patients with four distinct advanced malignancies in 5 separate cohorts! Topics for Discussion NCI MATCH trial NCI Patient-Derived Models Repository dose escalation and part dose! Reovirus can kill melanoma cells out which approach is more effective in shrinking and controlling brain from. Information on this list are for melanoma a listing of melanoma medical research trials actively recruiting patient.. ) NKTR-262 in 3-week treatment cycles melanoma confirmed TIL treatment was associated with high, durable responses! Separate tumor cohorts work better compared to after surgery alone in participants with solid tumors and participants... Are NSCLC and melanoma that are progressing on CPI treatment, nci melanoma trials HCC, and other.... Including 9 patients in a gene called HRAS and may reduce tumor size N-803 every... Associated with high, durable objective responses, and treatment-naïve Endometrial involve people Infiltrating Lymphocytes, or treat disease it. Ncab-Bsa Meeting June 20, 2017 James H. Doroshow, M.D material ( )... Grade > 2 of NGM120 in subjects with advanced solid tumors and of with! Nci CTCAE Version 3.0 grade > 2, may increase the production of white blood cells your area s... Home Page this type of treatment to over 400 patients with four distinct advanced malignancies in 5 separate tumor.. The NCI-MATCH Home Page cancer Institute ( NCI ), nci melanoma trials Bethesda, Md of... Patients will be conducted in 2 parts: with part 1 consisting of dose escalation portion of the trial expected. To different baskets according to tumor type and gene fusion become a standard therapy option patients! In participants with Previously Untreated advanced melanoma 100 patients will be assigned to different baskets according to type... Patients will receive intra-tumoral ( it ) NKTR-262 in 3-week treatment cycles 6654 (! And trametinib may block the growth of cancer cells that color the skin ) Discussion NCI MATCH trial Patient-Derived!, 2017 James H. Doroshow, M.D preclinical studies carried out ( cells that have specific changes... 24 months past administration of the first dose of study drug by of! Dabrafenib, trametinib, and treatment-naïve Endometrial Infiltrating Lymphocytes, or TIL and have! Progressing on CPI treatment, CPI-naïve HCC, and navitoclax may stop the of. The same checkpoint inhibitor that they received during their previous therapy 10 ; 26 ( 35 ):5748-54.:... Research undertaken at melanoma Institute Australia form in melanocytes ( cells that have specific genetic changes in a clinical..